Skip to main content
Premium Trial:

Request an Annual Quote

Chris van Ingen, Tim Harkness, Heiner Dreismann, Laurence McCarthy, Stuart Auerbach, Tarif Awad

Agilent Technologies last week said that Chris van Ingen, president of the Bio-Analytical Measurement business, will retire on Oct. 31, the last day of Agilent's fiscal year.
Van Ingen, 61, is a 30-year veteran of Agilent and Hewlett-Packard, which spun off Agilent in November 1999. He was appointed to his current position in May 2001.
Agilent did not say who will run the Bio-Analytical Measurement business beginning Nov. 1.
Agilent also announced that William Molnar has joined the firm as vice president and general manager of the Stratagene division. Molnar joins Agilent from EMD Chemicals, where he served as vice president and general manager of the firm’s lab business.

Nektar Therapeutics this week named former Molecular Devices CFO Tim Harkness senior vice president and chief financial officer.
Harkness, who replaces Louis Drapeau, will receive an annual base salary of $440,000, along with an option to purchase 200,000 shares of common stock, according to a filing with the US Securities and Exchange Commission.

Heiner Dreismann, former president and CEO of Roche Molecular Diagnostics, has joined the board of directors of Magellan Biosciences, a clinical diagnostics developer. Dreismann is one of three new board members for the firm. Also joining the board are Laurence McCarthy, former president and CEO of Focus Diagnostics, which was acquired by Quest Diagnostics last year, and Stuart Auerbach, a general partner at Ampersand Ventures.

Tarif Awad has joined VisEn Medical as director of external scientific collaborations. Awad comes to the firm from Affymetrix, where he was senior manager of pharmaceutical and industrial collaborations.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.